Leading causes of castration-resistant prostate cancer

被引：0
|
作者：
Lu, Mingqian [1 ,2 ,3 ]
Lu, Hongda [4 ,5 ]
Kong, Qingzhi [4 ,5 ]
机构：
[1] Hubei Univ Chinese Med, Clin Med Coll, Wuhan 430061, Hubei Province, Peoples R China
[2] China Three Gorges Univ, Dept Oncol, Yichang 443003, Hubei Province, Peoples R China
[3] Yichang Cent Peoples Hosp, Dept Oncol, Yichang 443003, Hubei Province, Peoples R China
[4] Cent Hosp Wuhan, Dept Oncol, Wuhan 430014, Hubei Province, Peoples R China
[5] Canc Res Inst Wuhan, Wuhan 430014, Hubei Province, Peoples R China
来源：
EXPERT REVIEW OF ANTICANCER THERAPY | 2015年 / 15卷 / 04期
基金：
湖北省教育厅重点项目;
关键词：
androgen receptor; androgen receptor mutation; androgen receptor splicing; castration-resistant prostate cancer; neuroendocrine; progenitor cells; ANDROGEN RECEPTOR GENE; EPIDERMAL-GROWTH-FACTOR; ANTIANDROGEN WITHDRAWAL SYNDROME; TRANSGENIC MOUSE MODEL; TUMOR-CELL LINES; NEUROENDOCRINE DIFFERENTIATION; STEM-CELLS; SPLICE VARIANTS; FULL-LENGTH; CASODEX BICALUTAMIDE;
D O I：
10.1586/14737140.2015.1007957
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Prostate cancer (PCa) is the second leading cause of cancer-related death in men. Androgen receptor has a key role in the initiation and progression of PCa. Currently, androgen deprivation therapy is the standard treatment for PCa patients due to its effective suppression of androgen receptor signaling. Even though androgen deprivation therapy shows its initial effectiveness on shrinking tumor size, it eventually fails to cure advanced PCa, which is determined by the occurrence of castration-resistance. In this review, we summarize the widely accepted mechanisms that account for castration-resistant PCa and discuss potential therapeutic targets.
引用
收藏
页码：425 / 432
页数：8
相关论文
共 50 条
  • [1] DIETHYLSTILBESTROL IN CASTRATION-RESISTANT PROSTATE CANCER OESTROGENS IN CASTRATION-RESISTANT PROSTATE CANCER: BACK TO THE FUTURE?
    Sartor, Oliver
    BJU INTERNATIONAL, 2012, 110 (11B) : E736 - E736
  • [2] Darolutamide For Castration-Resistant Prostate Cancer
    Bastos, Diogo A.
    Antonarakis, Emmanuel S.
    ONCOTARGETS AND THERAPY, 2019, 12 : 8769 - 8777
  • [3] Immunotherapy for Castration-Resistant Prostate Cancer
    Sonpavde, Guru
    Kantoff, Philip W.
    UROLOGIC CLINICS OF NORTH AMERICA, 2012, 39 (04) : 465 - +
  • [4] Chemotherapy for castration-resistant prostate cancer
    Berthold, D.
    ONKOLOGIE, 2011, 34 : 12 - 12
  • [5] Strategies in castration-resistant prostate cancer
    Bessede, Th
    PROGRES EN UROLOGIE, 2011, 21 : S68 - S71
  • [6] Metastatic castration-resistant prostate cancer
    Henriques, Vanessa
    Wenzel, Mike
    Demes, Melanie-Christin
    Koellermann, Jens
    PATHOLOGE, 2021, 42 (04): : 431 - 438
  • [7] Abiraterone and castration-resistant prostate cancer
    Burki, Talha Khan
    LANCET ONCOLOGY, 2013, 14 (02): : E48 - E48
  • [8] Diethylstilbestrol in castration-resistant prostate cancer
    Wilkins, Anna
    Shahidi, Mehdi
    Parker, Chris
    Gunapala, Ranga
    Thomas, Karen
    Huddart, Robert
    Horwich, Alan
    Dearnaley, David
    BJU INTERNATIONAL, 2012, 110 (11B) : E727 - E735
  • [9] The biology of castration-resistant prostate cancer
    Lian, Fei
    Sharma, Nitya V.
    Moran, Josue D.
    Moreno, Carlos S.
    CURRENT PROBLEMS IN CANCER, 2015, 39 (01) : 17 - 28
  • [10] Castration-resistant prostate cancer (CRPC)
    Loidl, W.
    Luger, F.
    Roosen, A.
    UROLOGE, 2014, 53 (03): : 391 - 399
12345